Biovica International AB is engages in the development and commercialization of novel blood-based biomarker assays to improve the monitoring of modern cancer therapies. It offers DiviTum assay, which is intended to monitor and predict treatment response in cancer patients. The company was founded in 2009 and is headquartered in Uppsala, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company